NNIT – Our growth strategy

Dansk Aktionærforenings InvestorDagen 2015

140

0

0

160

200

205

0

115

110

103

175

175

75

90

85

155

167

161

203

196

180

135

145

25

2

Disclaimer This presentation has been prepared and issued by, and is the sole responsibility of, NNIT A/S (“NNIT” and, together with its subsidiaries, the “Group”). For the purposes of this notice, the presentation that follows (the “Presentation”) shall mean and include the slides that follow, the oral

presentation of the slides by the Group, the question-and-answer session that follows that oral presentation, hard copies of this document and any materials distributed at, or in connection with, that presentation.

The Presentation does not constitute or form part of, and should not be construed as: (i) an offer, solicitation or invitation to subscribe for, sell or issue, underwrite or otherwise acquire any securities or financial instruments of NNIT (the “Securities”), nor shall it, or the fact of its

communication, form the basis of, or be relied upon in connection with, or act as any inducement to enter into any contract or commitment whatsoever with respect to any Securities; or (ii) any form of financial opinion, recommendation or investment advice with respect to any Securities.

The Presentation is private and confidential, has been furnished to you solely for your information and may not be reproduced, redistributed or disclosed in any way, in whole or in part, directly or indirectly, to any other person without the prior written consent of NNIT. The information

contained in the Presentation is provided as of the date hereof.

No person is under any obligation to update, complete, revise or keep current the information contained in the Presentation. The information contained in the Presentation must not be relied upon for any purpose.

No responsibility, obligation or liability (whether direct or indirect, in contract, tort or otherwise) is or will be accepted in relation to the Presentation by NNIT or any of its shareholders, their affiliates, their respective directors, officers, employees or agents, advisors or representatives,

including Morgan Stanley International & Co. plc (“Morgan Stanley”), its affiliates, their respective directors, officers, employees or agents (the “Morgan Stanley Group”), Danske Bank A/S (“Danske Bank”), its affiliates, their respective directors, officers, employees or agents (the “Danske

Bank Group”), Skandinaviska Enskilda Banken, Danmark, filial af Skandinaviska Enskilda Banken AB (publ), Sverige (“SEB”), its affiliates their respective directors, officers, employees or agents (the “SEB Group”, together with the Morgan Stanley Group and the Danske Bank Group, the

“Advisor Groups”) or by Novo Nordisk A/S and Novo A/S (together the “Controlling Shareholders”). Any and all liability which may be based on the Presentation and any errors therein or omissions therefrom or any loss arising from the use of or otherwise in connection with the

Presentation is expressly disclaimed by these parties. Morgan Stanley, Danske Bank and SEB are acting as financial advisors to NNIT and the Controlling Shareholders only and will not regard any other person (whether a recipient of the Presentation or not) as a client in relation to any

transaction regarding NNIT and will not be responsible to anyone other than NNIT and the Controlling Shareholders for providing the protections afforded to clients of Morgan Stanley and Danske Bank, respectively, nor for providing advice to any such other person.

The Presentation was prepared based solely on information obtained from NNIT and public sources on or prior to the date hereof and has not been independently verified. The Presentation contains only summary information and no representation or warranty, express or implied, is or

will be made in relation to, and no reliance should be placed on, the fairness, accuracy, correctness or completeness of the information or opinions contained herein. Moreover, the Presentation may include statements and illustrations concerning risks, plans, objectives, goals,

strategies, future events or performance, and underlying assumptions and other statements, which are other than statements of historical facts. Such statements and illustrations involve risks and uncertainties and neither NNIT nor any of its affiliates, shareholders or any of its or their

advisors or representatives, including the Controlling Shareholders and the Advisor Groups make any warranties or representat ions about accuracy, sequence, timeliness or completeness of the content of the Presentation or the achievement or reasonableness of future projections,

management targets, estimates, prospects or returns, if any. The Presentation includes market share and industry data obtained by NNIT from industry publications and surveys and internal surveys. NNIT may not have access to the facts and assumptions underlying the numerical data,

market data and other information extracted from publicly available sources. As a result, neither NNIT nor any of its affiliates, shareholders or any of its or their advisors or representatives, including the Controlling Shareholders and the Advisor Groups are able to verify such numerical

data, market data and other information and assume no responsibility for the correctness of any market share or industry data or other information included in the Presentation. Furthermore, and without prejudice to liability for fraud, no member of the Advisor Groups, NNIT or the

Controlling Shareholders accepts or will accept any liability, responsibility or obligation (whether in contract, tort or otherwise) in relation to these matters. Any prospective investor should make its own investigation of NNIT and all information provided and is advised to seek professional

advice on legal, financial, tax and other matters relating to the NNIT and any transaction contemplated herein.

Statements in the Presentation, including those regarding the possible or assumed future or other performance of the Group or its industry or other trend projections, constitute forward-looking statements. By their nature, forward-looking statements involve known and unknown risks,

uncertainties, assumptions and other factors because they relate to events and depend on circumstances that will occur in the future whether or not outside the control of the Group. Such factors may cause actual results, performance or developments to differ materially from those

expressed or implied by such forward-looking statements. Accordingly, no assurance is given that such forward-looking statements will prove to have been correct. They speak only as at the date of the Presentation and the Group undertakes no obligation to update these forward-

looking statements.

Any information and views contained herein do not purport to be comprehensive and are based on financial, economic, market and other conditions prevailing as of the date of the Presentation and are subject to change without notice. No person is under any obligation to update or keep

current the information contained in the Presentation.

No decision has been made on whether to proceed with a transaction regarding NNIT, but if such decision is made, any investment decision must be made exclusively on the basis of a prospectus or other offering document that will supersede the information in the Presentation. The

Presentation does not constitute nor is intended to form part of any offer, or the solicitation of any offer, to buy, subscribe for or sell any shares in NNIT or any other securities. Nor shall the Presentation or any part hereof form the basis of, or be relied on in connection with, any contract,

commitment or investment decision, nor do it constitute any form of financial opinion or recommendation regarding shares or other securities of NNIT on the part of any member of the Advisor Groups.

Without prejudice to liability for fraud, NNIT, the Controlling Shareholders and each member of the Advisor Groups, disclaims any liability which may be based on the Presentation or any other written or oral information provided in connection therewith and any errors therein and/or

omissions therefrom. The distribution of the Presentation in certain jurisdictions may be restricted by law and, accordingly, recipients of the Presentation represent that they are able to receive the Presentation without contravention of any unfulfilled registration requirements or other legal

restrictions in the jurisdiction in which they reside or conduct business.

The terms and conditions, under which the Presentation is provided, are governed by Danish law without regard to the choice of law principles.

The Presentation is not for distribution into the United States. The Presentation does not constitute an offer or solicitation to purchase or subscribe for securities in the United States. The securities to which the Presentation relates have not been registered, and will not be registered,

under the U.S. Securities Act of 1933, as amended (the U.S. Securities Act), or under the securities laws of any state or other jurisdiction of the United States and may not be offered or sold in the United States unless they are registered under the U.S. Securities Act or pursuant to an

exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act. There will be no public offering of securities in the United States.

In the United Kingdom, the Presentation is directed only at, and any investment or investment activity to which the Presentation relates is available only to, and will be engaged in only with, persons (i) who are investment professionals as defined in Article 19(5) of the Financial Services

and Markets Act 2000 (Financial Promotion) Order 2005 (the “Order”); or (ii) fall within Article 49(2)(a) to (d) of the Order (“high net worth companies, unincorporated associations etc.”) (all such persons being “relevant persons”). The Presentation is only for relevant persons and must

not be acted on, reviewed or relied on by persons who are not relevant persons.

In any member state of the European Economic Area, the Presentation is directed only at "qualified investors" within the meaning of Article 2(1)(e) of the Prospectus Directive (Directive 2003/71/EC and amendments thereto, including Directive 2010/73/EU to the extent implemented in a

relevant EEA member state).

The securities to which the Presentation relates have not been and will not be registered under the applicable securities laws of Australia, Canada or Japan and may not be offered or sold within Canada, Australia or Japan or to any national, resident or citizen of Australia, Canada or

Japan. Neither this Presentation (including any materials distributed in connection with this Presentation) nor any copy of i t may be taken or transmitted into the United States, its territories or possessions, into Australia, Canada or Japan or be distributed, directly or indirectly, into the

United States, its territories or possessions or to any U.S. person, as that term is defined under Regulation S of the U.S. Securities Act, or to any securities analyst or other person in any of the above jurisdictions. Any failure to comply with this restriction may constitute a violation of

United States, Australian, Canadian or Japanese securities law. The distribution of this Presentation in other jurisdictions may be restricted by law and persons into whose possession this Presentation comes should inform themselves about, and observe any, such restrictions.

Introduction to NNIT

• NNIT is one of the three largest providers of IT services in Denmark

• Focus areas: IT consultancy, development, implementation and operations for life sciences, finance, public and other industries

• We deliver solid quality methodical approaches, open and honest communication, and a high sense of delivering the right quality

• Trusted IT advisor to pharmaceutical companies. Our experience can be deployed to, e.g. the regulatory industries

• More than 2,400 employees

• Revenue in 2014 was DKK 2,410 million

• Head office in Soeborg, Denmark – offices in: China, Switzerland, Germany, the US, the Philippines and the Czech Republic

• Customers throughout Europe, the US and China

In brief

Vision 2020 Mission Values We are passionate

people building winning

teams with our

customers

By 2020, our quality

and value adding IT

services will make us:

• Denmark’s preferred

IT outsourcing

partner

• A leading

international IT

partner dedicated to

life sciences

Open and honest

Conscience driven

Value adding

NNIT Way Our values and mission will lead us towards our vision

140

0

0

160

200

205

0

115

110

103

175

175

75

90

85

155

167

161

203

196

180

135

145

25

6

Key investor highlights

Danish IT Market Leader

Top 3 Leading market share in IT services market

in Denmark and Fastest Growing Player (1)

Industry-Leading Margins

>10% Last 10 years operating margin

Sources: IDC Denmark IT Services Vendor Shares 2014, Valcon report based on third party data

Notes 1. Among top 10 Danish IT Services competitors in 2013 2. Based on Valcon analysis for 2014 including revenue from Novo Nordisk; excluding Novo Nordisk, market share would be 19% 3. Backlog represents anticipated revenue from contracts or orders executed but not yet completed or performed in full, and which revenue is expected to be recognised in the current or a future financial year; in order to arrive at the percentage, the

backlog is then divided by the actual revenue for the following year. The calculation of backlog is subject to a number of assumptions. Backlog as of any date is not necessarily a meaningful predictor of future revenue and projects included in backlog may be subject to cancellation, revision or delay. Turnover time from backlog to revenue varies significantly depending on what types of contracts constitute backlog

4. Defined as dividends paid on net profit for the previous fiscal year 5. As of 31st December 2014

Global Delivery Model

36% Percentage of FT Employees based outside

Denmark (5)

Healthy Backlog and High Visibility

>70% Revenue contracted for 2014 as a

percentage of 2014A total revenue as of 31

December 2013 (3)

Market Share Winner with Historical

Organic Revenue Growth

>10% Last 10 years average revenue growth rate

Life Sciences Leader

>40% Market Share in Danish Life Sciences IT

Services (2)

High Pay-out Ratio (4) Objective set at

40%

140

0

0

160

200

205

0

115

110

103

175

175

75

90

85

155

167

161

203

196

180

135

145

25

801 890

1.016

1.165

1.396

1.587 1.654

1.795

2.028

2.205

2.410

14%

12% 12% 12% 11%

12% 13% 11% 11% 11% 11%

1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014

7

Revenue Mix Development Since 2004

Non-Novo Nordisk Revenue

Novo Nordisk Revenue

Operating Margin (%)

Novo Nordisk vs. non-Novo Nordisk DKKm

Great Track Record of Profitable Growth while Diversifying Our Revenue Base

Novo Nordisk

separates its

IT activities

Per Kogut –

new CEO

10th consecutive

year with double

digit growth

New

Data

centre

Opening of

New Locations:

Novo Nordisk

IT incorporated

as a limited

liability

company (A/S)

Novo

Nordisk IT

renamed

NNIT

140

0

0

160

200

205

0

115

110

103

175

175

75

90

85

155

167

161

203

196

180

135

145

25

8

Leveraging Our Compliance DNA Drives Diversification

Finance

DKK 166m

(7%)

IT Solutions Services: Advisory services, business solutions and

application management

IT Operations Services: Infrastructure outsourcing and related

consulting, support services

DKK 743m

(31%)

DKK 1,667m

(69%)

Life

Sciences

DKK 1,547m

(64%)

Public

DKK 326m

(14%)

Enterprise

DKK 371m

(15%)

Our Core Leveraging Our Compliance DNA

Revenue 2014

(contribution to total - %) Note 1. Selection of current NNIT customers, as of February 2015

See Note (1)

Our growth strategy

140

0

0

160

200

205

0

115

110

103

175

175

75

90

85

155

167

161

203

196

180

135

145

25

11

The Key Pillars of Our Growth Strategy

Revenue 2013

(contribution to total - %)

Supporting Pillars

Win Profitable Market

Share

2020 S

trate

gy

In Denmark

Internationally

Increase our share of existing customers’ IT spending

Win new customers

Support Danish customers with their

internationalisation

Continue our cost efficiency efforts

Continue to promote the highest possible customer satisfaction

Enhance our brand and commercial profile

Maintain our vision/culture and enhance our Human Capital

Life Sciences

1

2

140

0

0

160

200

205

0

115

110

103

175

175

75

90

85

155

167

161

203

196

180

135

145

25

12

Denmark

Revenue 2013

(contribution to total - %)

Supporting Pillars

Win Profitable Market

Share

2020 S

trate

gy

In Denmark

Internationally

Increase our share of existing customers’ IT spending

Win new customers

Support Danish customers with their

internationalisation

Continue our cost efficiency efforts

Continue to promote the highest possible customer satisfaction

Enhance our brand and commercial profile

Maintain our vision/culture and enhance our Human Capital

Life Sciences

1

140

0

0

160

200

205

0

115

110

103

175

175

75

90

85

155

167

161

203

196

180

135

145

25

13

Hardware

Software

IT services

NNIT’s key

segment

01010011

01010111

3 Primary Areas Characterising the IT Market

IT market

Danish IT Services Market Estimated at a Total

Value of c. DKK 35bn in 2014 (1)

01010011

01010111

IT Services

DKK 35bn

49%

Software

DKK 13bn

18%

Hardware

DKK 24bn

33%

IT Services is a DKK 35bn Market…

Note 1. Total market defined as total spending Source: IDC 2014

140

0

0

160

200

205

0

115

110

103

175

175

75

90

85

155

167

161

203

196

180

135

145

25

Leading Market Share in Danish IT Services Market

Danish IT Services Market Development vs. NNIT

Danish IT Services Market (2013 Revenue (1)) DKKm

5.748

3.956

2.116

1.477 1.266 1.140 1.066 1.002 924

605

-

1.000

2.000

3.000

4.000

5.000

6.000

7.000

EG

14

(3%)

(0%)

+10%

(10%)

+1% (2%) +2% (1%)

+7% (7%)

+x% 2012-2013 YoY Growth

Source: IDC Nordic IT Services 2013 Vendor Shares

Note 1. Based on IDC’s estimates of Danish operations for these 10 competitors, may differ from reported numbers in companies’ filings

140

0

0

160

200

205

0

115

110

103

175

175

75

90

85

155

167

161

203

196

180

135

145

25

16

…With Space to Grow Further As The Leading Local Provider – As Seen In Other European Countries

Source: IDC (2014); Gartner (2014)

France

1st

9%

Spain

1st

9%

Denmark

6%

3rd

Norway

24%

1st Finland

1st

19%

Germany

9%

1st

Switzerland

11%

1st

Sweden

9%

1st

% market share and ranking

2013 Market Share of Leading Local IT Services Providers in Their Country of Origin

140

0

0

160

200

205

0

115

110

103

175

175

75

90

85

155

167

161

203

196

180

135

145

25

3,1

3,6

2014E 2020E

17

Market Overview Key Highlights

Life Sciences customer group includes pharma, medical

devices, contract research organisations and biotech

companies

Novo Nordisk is our largest customer, accounting

for approximately 81% (1) of the revenue in the Life

Sciences customer group in 2014

20+ years of experience with highly skilled

professionals dedicated to Life Sciences

Born in Life Sciences with “industry good practice” in our

blood but without the “one size fits all” approach of the

bigger players

Unique domain expertise in areas such as clinical data

warehouse, document management, serialisation and

AO GxP

Offering includes IT Solutions for Clinical

Development, Regulatory Affairs, Quality

Management, Supply Chain Management and GxP

Operations

Unique pre-qualified GxP Cloud solution specifically

designed for Life Sciences

Dedicated team of specialised Life Sciences

Consultants

Historical Revenue Progression

NNIT 44%

1.373 1.410 1.547

2012 2013 2014

+3%

Life Sciences Customer Group – Snapshot

Notes 1. 81% = 52% (Novo Nordisk) of 64% (Total Life Sciences) 2. Valcon report based on third party data – includes Novo Nordisk; excluding Novo Nordisk the market share would be 19%

Source: Valcon report based on third party data

DKKm

+10%

NNIT Addressable Market (DKK bn) NNIT Market share 2014 (2)

140

0

0

160

200

205

0

115

110

103

175

175

75

90

85

155

167

161

203

196

180

135

145

25

134

291

371

2012 2013 2014

18

Market Overview

Key Highlights

Comprises large Danish companies not

included in previous 3 groups, which are also

facing high regulation process activities and

quality control standards such as

manufacturing and food production

Focused on customers who need complex

solutions and centralised IT management in

Denmark

Successful integration of client employees

(e.g. Arla, Vestas) differentiates our business

Recent Vestas contract win helped to drive

2014 revenue

NNIT 6%

+118%

Enterprise Customer Group – Snapshot

Source: Valcon report based on third party data

Historical Revenue Progression

DKKm

Notes 1. Source: Valcon report based on third party data

+27%

NNIT Market share 2014 (1) NNIT Addressable Market (DKK bn)

6,6

7,3

2014E 2020E

140

0

0

160

200

205

0

115

110

103

175

175

75

90

85

155

167

161

203

196

180

135

145

25

19

Market Overview

Key Highlights

Comprises customers in the Danish central

and regional government as well as railways

Local government is only targeted to a certain

extent

Leverages our reputation and capitalises on

our “Danish” identity

Local data centre is a strong differentiator of

our business

Key growth areas include:

Healthcare solutions, such as patient journal

solutions and a telemedicine platform

NNIT 6%

357 345 326

2012 2013 2014

(3%)

Public Customer Group – Snapshot

Notes 1. Source: Valcon report based on third party data

Source: Valcon report based on third party data

Historical Revenue Progression

DKKm

(5%)

NNIT Addressable Market (DKK bn) NNIT Market share 2014 (1)

5,7 6,0

2014E 2020E

140

0

0

160

200

205

0

115

110

103

175

175

75

90

85

155

167

161

203

196

180

135

145

25

20

Market Overview

Key Highlights

Specifically targets banks, insurance

companies and pension companies

As financial institutions increasingly are required

to document and report business transactions,

we increasingly leverage our experience

working with customers in Life Sciences, to

other highly regulated industries

Offering includes security & compliance

consulting, project & programme management,

hosting of business critical applications such as

Tia, Edlund and Simcorp Dimension, cloud

services and a range of infrastructure

outsourcing services

Recent PFA contract win will help drive 2015

revenue

164 159 166

2012 2013 2014

Finance Customer Group – Snapshot

Note 1. Source: Valcon report based on third party data

Source: Valcon report based on third party data

Historical Revenue Progression

DKKm

(4%) 5%

NNIT Addressable Market (DKK bn) NNIT Market share 2014 (1)

1,8

2,0

2014E 2020E

NNIT 10%

140

0

0

160

200

205

0

115

110

103

175

175

75

90

85

155

167

161

203

196

180

135

145

25

21

A Unique Position in SAP

The SAP market is attractive, very complex and requires distinct process and technology knowledge

NNIT’s Attributes

A complex market with high competence requirements

NNIT is a leading SAP wall-to-wall supplier in Denmark

with 245+ dedicated SAP consultants including those

located offshore

Growth in our SAP project and SAP hosting revenues of

15% in 2014 (1)

Significant offshore presence of our SAP consultants

(42%) enabling NNIT to offer market conform prices (2)

Market leader within SAP PI/PO (integration)

Uniquely positioned within SAP to Life Sciences

(validated SAP, Serialisation)

Large potential for further growth of SAP AMS and SAP

hosting in enterprise segment in Denmark and in

International life sciences

Key Customers

Notes 1. Growth in NNIT’s SAP revenue 2. SAP consultants based offshore and nearshore represent 42% of NNIT’s total SAP consultants

Analytics Strategic

Enterprise

Management

Financial

Analytics

Operational

Analytics

Financials Financial

Accounting

Management

Accounting

Financial Supply

Chain

Management

HR Employee

Lifecycle

Management

Employee

Transaction

Management

HCM Service

Delivery

Operations:

Value

Creation

Procurement Inventory

and

Warehouse

Management

Manufacturing Transportation Sales Order

Management

Customer

Service

Operations:

Support

Life Cycle

Data

Management

Program and

Project

Management

Quality

Management

Corporate

Services

Travel

Management

Environment,

Health &

Safety

Incentive and

Commission

Management

SAP

Netweaver

People

Integration

Information

Integration

Process

Integration

Infrastructure

Industry Solutions

SAP Product Areas

Enterprise Asset Management

Real Estate Management

Application Integration

Appliances

Cross Solutions

Mobility

Workforce Analytics

Workforce Deployment

Corporate Governance

140

0

0

160

200

205

0

115

110

103

175

175

75

90

85

155

167

161

203

196

180

135

145

25

22

International

Revenue 2013

(contribution to total - %)

Supporting Pillars

Win Profitable Market

Share

2020 S

trate

gy

In Denmark

Internationally

Increase our share of existing customers’ IT spending

Win new customers

Support Danish customers with their

internationalisation

Continue our cost efficiency efforts

Continue to promote the highest possible customer satisfaction

Enhance our brand and commercial profile

Maintain our vision/culture and enhance our Human Capital

Life Sciences

1

2

140

0

0

160

200

205

0

115

110

103

175

175

75

90

85

155

167

161

203

196

180

135

145

25

23

…. Thanks to Leading-Edge Solutions Tailored to Life

Sciences

NNIT Delivers Value Added Solutions to Well-

Recognized Pharmaceutical Groups…

We Have a Strong Expertise in Life Sciences…

Unique, in-depth familiarity with

processes, requirements and terminology

associated with the life-sciences sector,

from R&D through to post-marketing

For example, industry-renowned expertise

on the following key service areas:

Serialisation

Clinical Data Warehousing

Validation Services

ISO IDMP

GxP Cloud: the first enterprise Cloud

platform dedicated to life sciences,

offering all the benefits of Cloud with

complete compliance and control

Largest Pharmaceutical Companies by Market Capitalisation

€bn

6 of the 10

largest Global

pharmaceutical

groups are our

clients today (1)

Source: Capital IQ as of February 2015

Note 1. 10 largest global pharmaceuticals by market capitalisation, based on CapitalIQ. Based on life sciences clients with whom NNIT has booked revenues in 2014

249

208

201

176

153

141

108

106

102

99

Johnson &Johnson

Novartis

Roche

Pfizer

Merck & Co

Gilead Sciences

Sanofi

Bayer

Amgen

Novo Nordisk

140

0

0

160

200

205

0

115

110

103

175

175

75

90

85

155

167

161

203

196

180

135

145

25

24

… And a Deep Array of Differentiated Solutions

Project

Services

Initiation/

Analysis

Application

Management

Integrated Drug

Development

• Clinical Information

Management

• R&D IT strategy

• eClinical

• CDW/SCE

• Safety

• Standardisation

• CTMS

• Portals

• Outsourcing

services

• Offshoring

Integrated

Quality

Management

• Compliance

Assessments

• Quality

Management

Framework

• QM outsourcing

• QMS maintenance

• SaaS Test

Management

• Project Quality

Management

• QM framework

• QMS

• SOP’s

• Audits

Integrated Supply

Chain

• Strategic Planning

• Manufacturing & SC

Advisory

• Quality Control

• Outsourcing

services

• Offshoring

• Serialisation

• PMO

• Quality

Management

Integrated Drug

Regulatory Affairs

• Regulatory

Information

Management

• RA IT strategy

• Outsourcing

services

• Offshoring

• eDMS

• eSubmission

• Portals

• IDMP

• RIMS

• Global labelling

Str

ate

gy

Desig

n/

Tra

nsit

ion

Op

era

tio

ns/

Co

nti

nu

ou

s

Imp

rov

em

en

t

Application

Support

• Application support

• Service Desk

• Onsite Support

• Application support

• Service Desk

• Onsite Support

• Application support

• Service Desk

• Onsite Support

Su

pp

ort

• Application support

• Service Desk

• Onsite Support

140

0

0

160

200

205

0

115

110

103

175

175

75

90

85

155

167

161

203

196

180

135

145

25

25

Life Sciences Industry is Expected to Increase Outsourcing Adoption…

Pharmaceutical Groups continue to seek reductions across their cost

base

Increasingly outsourcing R&D and manufacturing

Outsourcing of IT functions to efficient, high-quality and specialised

operators is therefore a likely trend

Recent Significant Cost Reductions Announced by Top Pharmaceutical

Groups

0.72%

Pharmaceutical Groups face Growing Pressures and

Continue to Seek Cost Reductions… … Driving Increasing Acceptance of Outsourcing,

Growing Faster than Other Industries

Source: Gartner, Vertical Forecast Worldwide Q4 2014

4,5

3,9 3,8 3,7

2,7

0%

1%

2%

3%

4%

5%

6%

Life Sciences Banking andSecurities

Utilities Transport Government

Projected 2013-2018 CAGR on IT Outsourcing Spending by

Vertical Industry Market (1) (%)

“…entails an estimated global headcount reduction of

about 5,050 [….] The overall programme remains on

track to deliver the approximately $800 million

anticipated annual benefits by the end of 2016”

Annual Report, 2013

“The initiative targets net reduction in annual

operating expenses of approximately $2.5 Bn by

the end of 2015 [...] Plan includes new workforce

reduction of approximately 8,500 positions”

Global Initiative Press Release, October 2013

Source: Company Filings Note 1. Outsourcing includes BPO and IT outsourcing 2. Merck & Co is not a customer of NNIT – but is used for illustrative purposes

AstraZeneca

Merck & Co (2)

140

0

0

160

200

205

0

115

110

103

175

175

75

90

85

155

167

161

203

196

180

135

145

25

26

NNIT is Well Positioned in a Growing International Life Sciences Target Market (1)

Total Market

DKK 207bn

NNIT Target

Market (1)

DKK 12.7bn = 6%

Total

Market

DKK 239bn

NNIT Target

Market (1)

DKK 14.7bn = 6%

2014 Target

Market (1)

DKK 12.7bn

2014 NNIT

Market Share

0.7%

2014 2020E

Western Europe (excl. Denmark) + US

… and Life Sciences Represent an Attractive Upside Opportunity

+2.5% CAGR

We currently address 6% of a

market growing at 2.5% CAGR

(2014-2020E)

In Denmark Life Sciences we have

a 44% market share as of 2013 (2)

We are a leader in the Danish life sciences IT services market and have opportunities to grow internationally

Source: Valcon report based on third party data

Note 1. The Target Market is a sub segment of the Total Addressable Market (“TAM”) based on selected target customers only; the TAM is a sub segment of the Total Market 2. Includes Novo Nordisk; excluding Novo Nordisk NNIT’s market share would be 19% in 2013

Guidance

140

0

0

160

200

205

0

115

110

103

175

175

75

90

85

155

167

161

203

196

180

135

145

25

28

Guidance / Outlook Statement

Long Term Target average growth in revenue of at least 5% in constant currencies

Target average operating profit margin of at least 10% in constant currencies

Cash Return Policy Our dividend policy has a initial target payout ratio of 40% of net profit

Capex

Capex for re-investments and normal operation in 2015 is estimated at c.5-6% of total net turnover

If NNIT decides to build another data center to support growth, NNIT expects additional capex of around DKK 250 million over a three-year period

2015

Revenue growth

5-8% at constant currencies(1)

Around 0.6pp higher as reported (2)

Operating margin

Around 11% at constant currencies(1)

Around 1.2pp lower as reported (2)

Note 1. Assuming average 2014 exchange rates 2. FX assumptions based on the following exchange rates at 31st January 2015: CNY/DKK 1.0253, EUR/DKK 0.74346, PHP/DKK 0.01424, USD/DKK 0.63500, CHF/DKK 0.72321, CZK/DKK 0.02670. Holding all other variables constant, a 10%

depreciation of the average 2014 exchange rate of the Danish kroner against the following currencies would have had the indicated impact on NNIT operating profit for 2014: CNY – (DKK14 MM); EUR – DKK11 MM; CZK – (DKK4 MM); PHP – (DKK3 MM); USD – (DKK1 MM); CHF – (DKK1 MM). The sensitivities address hypothetical situations and are provided for illustrative purposes only. These sensitivities assume our business develops consistent with our 2015 budget planning

140

0

0

160

200

205

0

115

110

103

175

175

75

90

85

155

167

161

203

196

180

135

145

25

29

Segmental Breakdown of Guidance

Segmental guidance

Segmental guidance should be seen as a guidance over time and not for individual years. This is due to the size of our segments where addition or loss of a single large contract can result in very volatile developments

Public Finance Enterprise Int’l Life

Science

Novo

Nordisk

≥5%

Growth above NNIT growth Growth in-line with NNIT growth Growth below NNIT growth Negative growth